No Data
dashenlin pharmaceutical group (603233): Stable growth on the revenue side, expecting improvement in profitability.
On October 30, the company released the third quarter performance report of 2024. In the first three quarters of 2024, revenue reached 19.731 billion yuan, a year-on-year growth of 11.33%, achieving a net income attributable to the parent of 8.58.
dashenlin pharmaceutical group (603233): Revenue growth is accelerating, and cost control is showing initial effectiveness.
Executive summary: The income is growing rapidly, mainly due to the rapid expansion outside the province, but the profitability level is relatively low, and the profit is under pressure in this stage. The company has optimized the gross margin and cost structure through various ways, with initial results seen, maintaining a shareholding rating. Investment highlights: Maintaining shareholding.
dashenlin pharmaceutical group (603233): Performance meets expectations Deepen national layout.
Items: The company announced that the revenue, net profit attributable to the mother, and non-net profit for the first three quarters of 24 were 19.73, 0.86, 0.85 billion yuan, with year-on-year changes of +11.3%, -26.9%, -26.8%, among which the income and net profit for the third quarter of 24 were
dashenlin pharmaceutical group (603233): steady growth in performance, rapid expansion of franchise stores
Event: The company released the third quarter report of 2024, achieving revenue of 19.73 billion yuan in the first three quarters (+11.3%), achieving a net income of 0.86 billion for the attributable parent (-26.3%), achieving a non-recurring net profit of 8.5 billion.
Dashanlin: Dashanlin Pharmaceutical Group Co., Ltd. Third Quarter Report 2024
Announcement of Dashenlin Pharmaceutical Group Co., Ltd. on the main operating data for the third quarter of 2024
No Data
No Data